Rifaximin

Structural elucidation of the Rifaximin Ph. Eur. Impurity H
Riccardo Stradi, Donatella Nava, Marino Nebuloni, Barbara Pastura, ElenaPini
Journal of Pharmaceutical and Biomedical Analysis Volume 51, Issue 4, 11 March 2010, Pages 858-865
 
Structure Elucidation of Two Unknown Oxydic Degradation Impurities of Rifaximin
chao liu, chang-qin hu  and shao-hong jin
Asian Journal of Chemistry; Vol. 23, No. 7 (2011), 3252-3256
 
Development and validation of rp-hplc method for the estimation of rifaximin in bulk and in tablet dosage form
T.sudha, P.V.hemalatha, V.R.ravikumar,r.jothi, M.radhakrishnan
Asian Journal of Pharmaceutical and Clinical Research Vol.2 Issue 4, October-December 2009
 
Stability Indicating HPTLC Method for Analysis of Rifaximin in Pharmaceutical Formulations and an Application to Acidic Degradation Kinetic Study
Kalpana G. Patel , Nitesh R. Jain, and Purvi A. Shah
Hindawi Publishing Corporation ISRN Analytical Chemistry Volume 2013, Article ID 613218, 9 pages

Rifaximin is chemically (2S,16Z,18E,20S,21S,22R,23R,24R,25S,26R,27S,28E)-25-(Acetyloxy)-5,6,21,23-tetrahydroxy-27-methoxy-2,4,11,16,20,22,24,26-octamethyl-2,7-(epoxypentadeca[1,11,13]trienimino)benzofuro[4,5-e]pyrido[1,2-a]benzimidazole-1,15(2H)-dione ; Normix ; Xifaxan ; Rifamycin L 105 . Rifaximin is supplied with detailed characterization data compliant with regulatory guideline. Rifaximin can be used for the analytical method development, method validation (AMV), Quality Controlled (QC) application for Abbreviated New Drug Application (ANDA) or during commercial production of Rifaximin.

The product can be used as reference standards and further traceability against pharmacopeial standards (USP or EP) can be provided based on feasibility. SynZeal products are for analytical purpose only and not for human use.